… -amplified Progs (including one dabrafenib-resistant BRAF-… 7 confirmed significantly elevated
MAPK signalling in the … in melanomas progressing on combination dabrafenib/trametinib (4/…

… treatment groups eventually began to acquire MAPK inhibitor resistance, as evidenced by the
reactivation … Furthermore, we report a partial response to dabrafenib + trametinib in patient …

… trametinib delivered by oral gavage daily suppressed MAPK … anti-growth effect than dabrafenib
as well as a significant … alone, combined BRAF V600E and MEK inhibitor treatment was …

… or BRAF plus MEK inhibitor combination therapy in patients with … benefit from MAPK-targeted
therapy with the combination of a … dabrafenib plus trametinib during the first MAPK-targeted …

… same combination after previously experiencing progression. At initial treatment with dabrafenib
plus trametinib… resistance, which mostly involves reactivation of the MAPK pathway 6–9 . …

… in paradoxical activation of the MAPK pathway in BRAF-… dabrafenib plus trametinib in
patients with BRAF V600–mutant melanoma (42). When dabrafenib and trametinib were combined …

… of BRAF and MEK inhibitors (dabrafenib and trametinib) in patients with … MAPK pathways
are reactivated by the BRAF mutation, MEK (MAPK Kinase) inhibitors, including trametinib…

… Dabrafenib combined with trametinib was superior to dabrafenib alone or vemurafenib alone,
and … BRAF and MEK inhibition and frequent reactivation of RAF/MEK/ERK signaling as a …

… plus trametinib appears to be an improvement on single-agent BRAF inhibition. Early efforts
… MEK combination therapy, with the first report revealing that reactivation of MAPK continues …

… In melanoma, resistance often involves reactivation of MAPK … pembrolizumab with dabrafenib
and trametinib combination. … with dabrafenib and trametinib or dabrafenib and trametinib in …